Particle.news
Download on the App Store
19 ARTICLES
·
4d ago

Trump Orders Crackdown on Drug Ads With FDA Launching Sweeping Enforcement

The move directs regulators to require fuller in‑ad risk disclosures across TV and social platforms.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
US President Donald Trump speaks during a Religious Liberty Commission meeting at the Museum of the Bible in Washington, DC, US, on Monday, Sept. 8, 2025. The Religious Liberty Commission, a panel created through an executive order earlier this year, is holding a hearing on religious liberty in public education. Photographer: Nathan Howard/Bloomberg via Getty Images
Image
US President Donald Trump, flanked by US Vice President JD Vance, speaks to reporters outside a DC restaurant

Overview

  • FDA is issuing about 100 cease‑and‑desist notices and thousands of warning letters to enforce existing rules on fair balance and side‑effect disclosures.
  • The administration plans regulations to end the 1997 “adequate provision” approach, requiring more complete risk information within ads that could lengthen broadcasts.
  • Scrutiny expands beyond traditional TV to social media influencers, online pharmacies and telehealth advertisers that have promoted drugs without proper disclosures.
  • Officials cite a sharp drop in oversight, noting one enforcement letter in 2023 and none in 2024, and describe the action as the strongest step short of a ban.
  • PhRMA stressed First Amendment protections for truthful advertising as officials declined to name letter recipients and referenced a criticized Hims & Hers Super Bowl spot as an example.